araag2/HINT huggingface dataset:
Clinical trial NCT01165385 (phase 1, status: completed)
Conditions: solid tumors, metastatic cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: cisplatin, pazopanib
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Main Inclusion Criteria:

          -  Documented metastatic solid malignancies for patients who are candidate to receive a
             cisplatin based regimen.

               -  During the dose seeking procedure : ALL solid tumors

               -  During the Optimal Tolerated Regimen validation procedure : ONLY HER2-RH- breast
                  cancer

          -  Measurable or evaluable disease

          -  WHO performance status ≤ 1

          -  Negative dipstick proteinuria test or if positive proteinuria <1g/24h. If proteinuria
             appears ≥ 2+ on routine dipstick testing, patients must undergo a 24H -urine
             collection and demonstrate proteinuria < 1g/24H

          -  Corrected QT interval (QTc) ≤ 480 msecs using Bazett's formula

        Main Exclusion Criteria:

          -  Prior treatment with cisplatin reaching a cumulative dose> 300 mg/m2

          -  HER2 positive breast cancer

          -  Patients at high risk of bleeding

          -  Clinically significant gastrointestinal abnormalities that may affect absorption of
             investigational product

          -  calcium and magnesium levels inferior to standard levels (measured within 14 days
             before the first pazopanib dose) and potassium levels inferior to standard levels
             (measured within 72 hours before the first pazopanib dose)

          -  Patients with other concurrent severe and/or uncontrolled medical disease which could
             compromise participation in the study

          -  Hearing impairment/tinnitus > or = grade 2
Clinical trial NCT00625651 (phase 1/phase 2, status: completed)
Conditions: metastatic colorectal cancer, colon cancer, colorectal cancer, rectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C18.2, C18.4, C18.6, C18.7, C18.9, D12.2, D12.3, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: placebo, amg 655, modified folfox6, bevacizumab
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed metastatic adenocarcinoma of the colon or
             rectum.

          -  Subjects with measurable or unmeasurable disease

          -  Eastern Cooperative Oncology Group (ECOG) score of 0 or 1

          -  Men or women at least 18 years of age

          -  Adequate hematologic, renal, hepatic and coagulation function

        Exclusion Criteria:

          -  History or known presence of central nervous system (CNS) metastases

          -  Prior chemotherapy or other systemic therapy for advanced or metastatic CRC

          -  Any investigational agent or therapy for advanced or metastatic CRC

          -  Clinically significant cardiac disease

          -  Clinically significant peripheral neuropathy

          -  Active inflammatory bowel disease

          -  Recent gastrointestinal ulcer or hemorrhage

          -  Recent arterial thrombotic event or pulmonary embolus

          -  Recent history of clinically significant bleeding, bleeding diathesis, or coagulopathy

          -  Recent major surgical procedure or not yet recovered from major surgery
Clinical trial NCT00307723 (phase 1/phase 2, status: terminated)
Conditions: pancreatic cancer, pancreatic ductal adenocarcinoma
ICD codes: C25.3, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: bevacizumab, 5-fluorouracil, oxaliplatin, gemcitabine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, FC1=CNC(=O)NC1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    poor accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically and radiologically confirmed locally advanced pancreatic ductal
             adenocarcinoma and have not received prior therapy

          -  Disease is measurable by CT scan

          -  Age >= to 18 years

          -  Life expectancy of 4 months or longer

          -  ANC >/= 1,500mm/cm3

          -  Hemoglobin >/= 9g/dl

          -  Platelet count >/= 100,000/cm3

          -  Total bilirubin </= 2 times control

          -  SGOT/SGPT </= 2.5 times upper limit of normal

          -  Serum creatinine < 2mg/dl

          -  No evidence of metastatic disease by laparoscopy

        Exclusion Criteria:

          -  History of other disease, metabolic dysfunction, physical examination finding, or
             clinical laboratory finding giving reasonable suspicion of a disease or condition that
             contraindicates the use of an investigational drug or that might affect the
             interpretation of the results of the study or render the subject at high risk for
             complications

          -  No secondary malignancies other than non-melanoma skin cancers or carcinoma in-situ of
             the cervix within past 5 years

          -  Patients with pre-existing peripheral neuropathy of grade 2 or greater

          -  Pregnant or lactating women

          -  Current, recent (within 4 weeks of study entry) or planned participation in an
             experimental drug study

          -  Blood pressure of >150/100 mmHg

          -  Unstable angina

          -  New York Heart Association Grade II or greater congestive heart failure

          -  History of myocardial infarction or stroke within 6 months

          -  Clinically significant peripheral vascular disease

          -  Evidence of bleeding diathesis or coagulopathy

          -  Presence of central nervous system or brain metastases

          -  Major surgical procedure, open biopsy,m or significant traumatic injury within 28 days
             prior to day 0

          -  Minor surgical procedures, fine needle aspirations or core biopsies within 7 days
             prior to day 0

          -  Urine protein creatinine ratio > or = to 1.0 at screening

          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
             within 6 months prior to day 0

          -  Serious, non-healing wound, ulcer, or bone fracture
Clinical trial NCT00607399 (phase 1, status: terminated)
Conditions: advanced cancer
ICD codes: K74.02, G47.22, H35.3133, H35.3134, H35.3113, H35.3114, H35.3123
Drugs: sgx523 capsules
SMILES: CN1C=C(C=N1)C1=NN2C(SC3=CC=C4N=CC=CC4=C3)=NN=C2C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Subject has the ability to understand, able, willing to comply with study procedures
             and follow up visits, and has provided written consent.

          -  Pathologic evidence of solid tumor.

          -  Failed standard therapy and deemed by the Investigator to be suitable for
             participation into the trial.

          -  Laboratory values (obtained within 10 days prior to enrollment): ANC: >= 1.5 × 109/L;
             Platelets: >= 100 × 109/L; Hemoglobin: >= 10.0 g/dL (without transfusions); Bilirubin:
             within normal range; AST, ALT, and alkaline phosphatase: <= 2.5 x ULN without tumor
             liver involvement; Serum creatinine: within normal limits; Calculated creatinine
             clearance: >= 60 mL/min/1.73 m2 for patients with creatinine > Institutional Normal
             Values; PT/PTT/INR: within normal limits.

          -  Have IHC evidence of phospho-MET expression on tumor material no more than 12 months
             old. This is a requirement only for entry into the MTD dose expansion phase.

          -  Have no residual toxic effects of previous therapy, and undergo a washout period of at
             least 5 half-lives from the time of administration of the previous therapy.

        Exclusion Criteria:

          -  Pregnant, lactating, or may become pregnant.

          -  Cardiac disease requiring medical therapy.

          -  Have had a major surgery within 4 weeks prior to Day 1 of the study

          -  Have an active, uncontrolled bacterial, viral, or fungal infection that requires
             ongoing systemic therapy.

          -  Have a known active infection with HIV, hepatitis B or C.

          -  Have psychiatric or seizure disorders that would require therapy or interfere with
             study participation.

          -  Have other severe concurrent nonmalignant disease that could compromise protocol
             objectives, including malabsorptive conditions.

          -  Patients receiving prohibited medications as listed in Appendix E, including drugs
             categorized as strong inhibitors of CYP3A4 and A5 and drugs known to have a high
             potential risk of liver toxicity.

          -  Have known allergy to SGX523 formulation or its excipients (croscarmellose sodium,
             lactose monohydrate and magnesium stereate).

          -  Patients receiving anti-coagulant therapy.
Clinical trial NCT01132911 (phase 1, status: completed)
Conditions: lymphoma, sarcoma, wilmstumor, neuroblastoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, C96.A, C46.9, C96.22, C46.0, C46.2, C92.31, C92.32
Drugs: vorinostat (saha), velcade (ps-341, bortezomib)
SMILES: ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1, CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
Eligibility criteria:

        -  Eligibility Criteria:

        Inclusion Criteria:

          -  Patients older than12 months and less than or equal to 21 years of age with a
             diagnosis and histologic verification (except patients with instrinsic brain stem
             tumors, optic pathway gliomas or pineal tumors) of measureable or evaluable relapsed
             or refractory solid tumors including CNS tumors and lymphomas are eligible.

          -  Current disease state must be one for which there is no known curative therapy, or
             therapy proven to prolong survival.

          -  Performance score: Karnofsky greater than or equal to 60% for patients greater than 16
             years of age; Lansky greater than or equal to 60 for patients less than or equal to 16
             years of age.

          -  Must have fully recovered from acute toxic effects from all prior therapy which have
             been completed within the specified prior time frame.

          -  Have adequate organ function as determined by laboratory evaluation.
Clinical trial NCT00566241 (phase 1, status: terminated)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: recombinant human igf-1, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    insufficient recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of cystic fibrosis as proven by either sweat chloride or DNA analysis.

          -  Age >= 18 yr.

          -  Tanner stage: Femake Breasts: 4-5 Male Genitalia: 4-5

        Exclusion criteria:

          -  Hemoglobin A1C > 8.5 %

          -  Diabetic retinopathy

          -  Obstructive sleep apnea

          -  Respiratory failure requiring mechanical ventilation.

          -  Status post pulmonary transplantation.

          -  Concurrent or recent (within past 6 months) receipt of human growth hormone.

          -  History of adverse side effects to growth hormone other than carbohydrate intolerance.

          -  Pregnancy or attempting pregnancy.

          -  Women who are breast feeding.

          -  Sexually active women who refuse to use or are incapable of responsibly using reliable
             contraception.

          -  Proven non compliance with medical regimens.

          -  Inability or refusal to take subcutaneous injections.

          -  Known allergy to components in the IGF-I preparation.
Clinical trial NCT00362713 (phase 1, status: completed)
Conditions: urothelial carcinoma
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: ipilimumab
SMILES: COC1=CC=CC=C1OCC(O)CO
Eligibility criteria:

        Inclusion Criteria:

          -  Previously untreated urothelial cancer requiring surgery for treatment

          -  Ineligible for chemotherapy

          -  Adequate hematologic, kidney and liver function

        Exclusion Criteria:

          -  Sexually active and fertile individuals or partners of these individuals who are
             unwilling or unable to use an acceptable method of birth control for the entire trial
             and up to 4 weeks after the study

          -  Women who are pregnant or breastfeeding

          -  Women with a positive pregnancy test on enrollment prior to study drug administration

          -  Prior treatment with ipilimumab or other anti-CTLA4 antibody, or a CD137 agonist

          -  Concurrent malignancy, with the exception of adequately treated and cured basal or
             squamous cell skin cancer, or carcinoma in situ of the cervix (previous malignancy
             without evidence of disease for 5 years will also be allowed to enter trial)

          -  Autoimmune disease: subjects with a documented history of inflammatory bowel disease
             (including Crohn's disease and ulcerative colitis) are excluded from this study as are
             patients with a history of symptomatic disease (e.g., rheumatoid arthritis, systemic
             progressive sclerosis [scleroderma], Systemic Lupus Erythematosus, autoimmune
             vasculitis [e.g., Wegener's Granulomatosis]). Subjects with motor neuropathy
             considered of autoimmune origin (e.g., Guillain-Barre Syndrome) are excluded from this
             study

          -  Patients deemed ineligible for surgery

          -  Any non-oncology vaccine therapy used for prevention of infectious diseased in the
             past month

          -  Concomitant therapy with any of the following: IL-2, interferon or other non-study
             immunotherapy regimens, chemotherapy; immunosuppressive agents; other investigation
             therapies; or chronic use of systemic corticosteroids (used in the management of
             cancer or non-cancer related illnesses)

          -  Prior radiation therapy for urothelial cancer

          -  Positive screening tests for or any prior history of HIV, Hepatitis B or Hepatitis C
Clinical trial NCT00088556 (phase 1/phase 2, status: completed)
Conditions: carcinoma, non-small-cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: tlk286, carboplatin, paclitaxel
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          -  18 years of age or older

          -  Histologically confirmed non-small cell lung cancer (NSCLC)

          -  Stage IV or IIIB (disease that is not eligible for combined modality chemotherapy and
             radiation)

          -  Measurable disease by RECIST

          -  ECOG status of 0-1

          -  Adequate liver and renal function

          -  Adequate bone marrow reserves

        Exclusion Criteria:

          -  Prior chemotherapy, immunotherapy or biologic therapy for metastatic NSCLC

          -  Up to one prior adjuvant or neoadjuvant chemotherapy is allowed

          -  History of bone marrow transplantation or stem cell support

          -  Pregnant or lactating women
Clinical trial NCT00791544 (phase 1/phase 2, status: terminated)
Conditions: liver carcinoma
ICD codes: C22.0, D01.5, C22.7
Drugs: ave1642, sorafenib, erlotinib
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
Reason stopped: 
    company decision to discontinue the ave1642 development program, not due to any safety or
    efficacy concerns
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients not eligible for surgical resection, liver transplantation, local ablation
             techniques or chemoembolisation and with histologically proven liver carcinoma
             whenever possible or combination of radiologically documented hypervascular liver
             tumour and α foeto protein level ≥ 400 ng/ml

          -  Signed and dated approved patient informed consent form prior to enrollment into the
             study

        Exclusion Criteria:

          -  ECOG performance status > 2

          -  Inadequate organ function:

               -  Neutrophils (ANC) < 1,500/mm3

               -  Hemoglobin < 10g/dl

               -  Platelets < 100,000/mm3

               -  Total bilirubin > 1.5 x ULN

               -  ASAT, ALAT > 3 x ULN

               -  Creatininemia > 1.5 x ULN (or ≥ 2.0 mg/dl)

               -  INR > 1.6

               -  Liver cirrhosis Child Pugh B or C (score > 6)

               -  HbA1C > 8%

          -  No measurable or evaluable tumoral lesion

          -  Patients not eligible for sorafenib therapy and for whom this therapy cannot be
             postponed by 3 weeks (during AVE1642 single treatment period) in dose escalation part

          -  Prior exposure to an anti-IGF-1R class compound

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT01483781 (phase 1, status: completed)
Conditions: diabetes mellitus, type 2, plasma volume
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: canagliflozin, placebo
SMILES: [H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  All patients must have a diagnosis of T2DM with inadequate glycemic control (ie, HbA1c
             of >=7.0% and <=9.0% at Screening) on metformin monotherapy and be receiving therapy
             with an antihypertensive agent (an ACEI or ARB) for at least 4 weeks prior to
             Screening

        Exclusion Criteria:

        -History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta cell
        transplantation, or diabetes secondary to pancreatitis or pancreatectomy; or a severe
        hypoglycemic episode within 6 months before screening
Clinical trial NCT00522886 (phase 1, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: cetuximab
SMILES: [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed non-small cell lung cancer

          -  Inoperable stage III (UICC 2002; sixth edition) (no pleural effusion)

          -  WHO performance status 0 or 1

          -  Less than 10% weight loss in the last 6 months

          -  Lung function: FEV1 at least 50% and DLCO at least 50% of the predicted value

          -  No recent severe cardiac disease

          -  Adequate bone marrow function

          -  Adequate renal function

          -  Adequate hepatic function

          -  Life expectancy more than 6 months

          -  Measurable cancer

          -  Willing and able to comply with study prescriptions

          -  18 years or older

          -  Not pregnant or breast feeding

          -  Written informed consent

          -  No previous radiotherapy to the chest

        Exclusion Criteria:

          -  Not non-small cell lung cancer histology

          -  Mixed pathology

          -  History of prior chest radiotherapy

          -  Recent (<3 months) myocardial infarction

          -  Uncontrolled infectious disease

          -  Less than 18 years old

          -  Inadequate pulmonary function

          -  Other active malignancy
Clinical trial NCT00471367 (phase 1, status: terminated)
Conditions: lymphoma, nhl, non-hodgkin lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: azd4877
SMILES: CC(C)C(N(CCCN)C(=O)C1=CC=C(C)C=C1)C1=NC2=C(C(C)=NS2)C(=O)N1CC1=CC=CC=C1
Reason stopped: 
    part b of the study was terminated early due to a lack of enrollment.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Part A: Advanced solid tumors (including lymphoma without bone marrow involvement) for
             which standard treatment doesn't exist or is no longer effective.

          -  Part B: B-cell non-Hodgkin lymphoma that is not eligible for curative therapy or has
             relapsed.

          -  Relatively good overall health other than your cancer

        Exclusion Criteria:

          -  Poor bone marrow function (not producing enough blood cells). Serious heart
             conditions. Poor liver or kidney function
Clinical trial NCT00506805 (phase 1, status: completed)
Conditions: cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: snx-5422
SMILES: CC1(C)CC2=C(C(=NN2C2=CC(N[C@H]3CC[C@@H](CC3)OC(=O)CN)=C(C=C2)C(N)=O)C(F)(F)F)C(=O)C1
Eligibility criteria:

        Inclusion Criteria:

          -  >18 years old

          -  histologically confirmed solid tumor malignancy

          -  refractory to available therapy or for which no therapy is available

          -  adequate organ function

        Exclusion Criteria:

          -  CNS malignancy

          -  significant GI disease

          -  at risk for prolonged QT interval
Clinical trial NCT03069144 (phase 1/phase 2, status: completed)
Conditions: psoriasis, psoriasis vulgaris
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50, L40.0
Drugs: hat1 topical solution, calcipotriol
SMILES: O[C@H](\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)C1CC1
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of psoriasis with a psoriasis area and severity index (PASI) score
             > 3 and < 12

          -  Treatment area amenable to topical treatment

          -  Attending a hospital outpatient clinic or the private practice of a dermatologist

          -  Males or Females between 18-65 years

        Exclusion Criteria:

          -  Systemic treatment with immunosuppressive drugs or corticosteroids within 4 weeks
             prior to enrollment. (Inhaled or intranasal steroids for asthma or rhinitis may be
             used)

          -  Topical treatment with immunomodulators or corticosteroids within 4 weeks prior to
             enrollment.

          -  Phototherapy therapy within 4 weeks prior to enrollment or other topical therapy on
             the treatment area within 1 week prior to enrollment.

          -  Patients requiring any other topical or systemic medications that could affect the
             course of psoriasis during the study period.

          -  Clinical infection on the treatment area or patients with history of cancer including
             skin cancer, history of an immunocompromised disease.

          -  Current participation in any other interventional clinical trial

          -  History of allergy of any components in HAT1 or previously treated with HAT1

          -  Subjects with intense sun exposure during the study

          -  Patients known or suspected of not being able to comply with a trial protocol (e.g.
             alcoholism, drug dependency, or psychotic state)

          -  Patients that are currently pregnant or lactating or planning to become pregnant in
             the next 6 months